Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(1):17–27. doi: 10.1038/bjc.1997.4

Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line.

J J Pink 1, M Fritsch 1, M M Bilimoria 1, V J Assikis 1, V C Jordan 1
PMCID: PMC2222702  PMID: 9000593

Abstract

We have cloned and characterized a 77-kDa oestrogen receptor (ER) from an oestrogen-independent subclone of the MCF-7 human breast cancer cell line. This receptor contains an in-frame, tandem duplication of exons 6 and 7, located in the steroid-binding domain of the ER. This mutation has abrogated ligand binding, but not DNA binding, in this mutant ER. We previously described the partial structure of a unique oestrogen receptor (ER) that is expressed in an oestrogen-independent MCF-7:2A subclone of the breast cancer cell line MCF-7 (Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC 1996a, Nucleic Acids Res 24 962-969). Sequence analyses determined the molecular weight of this 80-kDa ER to be 77 kDa, and hereafter this protein will be designated as ER77. Examination of the entire coding sequence of the ER77 mRNA indicates that it contains a tandem duplication of exons 6 and 7. Using a coupled transcription/translation system, a 77-kDa ER, which corresponds to the protein observed in the MCF-7:2A cells, was expressed. The ER77 protein does not bind the ligands [3H] oestradiol or [3H]tamoxifen aziridine. In DNA binding gel shift assays, the in vitro synthesized ER77 binds to a consensus vitellogenin A2 oestrogen-response element. In transient transfection experiments, the mutant ER, alone or in combination with the wild-type ER, does not induce expression of an oestrogen-responsive luciferase reporter construct. In fact, expression of the ER77 in the ER-positive T47D:A18 cell line inhibits E2-induced luciferase expression. Overexpression of wild-type ER in T47D:A18 cells leads to elevated constitutive expression of the luciferase reporter, which was inhibited by co-transfection with ER77. These data suggest that the ER77 can interfere with normal ER activity and does not act as a constitutive activator of oestrogen-independent growth in MCF-7:2A cells. Consequently, the constitutive growth observed in MCF-7:2A cells is probably the result of other ER-mediated pathways.

Full text

PDF
18

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badley J. E., Bishop G. A., St John T., Frelinger J. A. A simple, rapid method for the purification of poly A+ RNA. Biotechniques. 1988 Feb;6(2):114–116. [PubMed] [Google Scholar]
  2. Berthois Y., Katzenellenbogen J. A., Katzenellenbogen B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2496–2500. doi: 10.1073/pnas.83.8.2496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brooks S. C., Locke E. R., Soule H. D. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem. 1973 Sep 10;248(17):6251–6253. [PubMed] [Google Scholar]
  4. Cailleau R., Young R., Olivé M., Reeves W. J., Jr Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 1974 Sep;53(3):661–674. doi: 10.1093/jnci/53.3.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Catherino W. H., Jordan V. C. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett. 1995 May 25;92(1):39–47. doi: 10.1016/0304-3835(95)03755-l. [DOI] [PubMed] [Google Scholar]
  6. Cho H., Katzenellenbogen B. S. Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Mol Endocrinol. 1993 Mar;7(3):441–452. doi: 10.1210/mend.7.3.7683375. [DOI] [PubMed] [Google Scholar]
  7. Fritsch M., Anderson I., Gorski J. Structural characterization of the trypsinized estrogen receptor. Biochemistry. 1993 Dec 21;32(50):14000–14008. doi: 10.1021/bi00213a033. [DOI] [PubMed] [Google Scholar]
  8. Fritsch M., Leary C. M., Furlow J. D., Ahrens H., Schuh T. J., Mueller G. C., Gorski J. A ligand-induced conformational change in the estrogen receptor is localized in the steroid binding domain. Biochemistry. 1992 Jun 16;31(23):5303–5311. doi: 10.1021/bi00138a009. [DOI] [PubMed] [Google Scholar]
  9. Green S., Issemann I., Sheer E. A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res. 1988 Jan 11;16(1):369–369. doi: 10.1093/nar/16.1.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Greene G. L., Fitch F. W., Jensen E. V. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. Proc Natl Acad Sci U S A. 1980 Jan;77(1):157–161. doi: 10.1073/pnas.77.1.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ince B. A., Zhuang Y., Wrenn C. K., Shapiro D. J., Katzenellenbogen B. S. Powerful dominant negative mutants of the human estrogen receptor. J Biol Chem. 1993 Jul 5;268(19):14026–14032. [PubMed] [Google Scholar]
  12. Jiang S. Y., Langan-Fahey S. M., Stella A. L., McCague R., Jordan V. C. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol. 1992 Dec;6(12):2167–2174. doi: 10.1210/mend.6.12.1491696. [DOI] [PubMed] [Google Scholar]
  13. Jiang S. Y., Wolf D. M., Yingling J. M., Chang C., Jordan V. C. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol. 1992 Dec;90(1):77–86. doi: 10.1016/0303-7207(92)90104-e. [DOI] [PubMed] [Google Scholar]
  14. Katzenellenbogen B. S., Kendra K. L., Norman M. J., Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 1987 Aug 15;47(16):4355–4360. [PubMed] [Google Scholar]
  15. Keydar I., Chen L., Karby S., Weiss F. R., Delarea J., Radu M., Chaitcik S., Brenner H. J. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer. 1979 May;15(5):659–670. doi: 10.1016/0014-2964(79)90139-7. [DOI] [PubMed] [Google Scholar]
  16. Kumar V., Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell. 1988 Oct 7;55(1):145–156. doi: 10.1016/0092-8674(88)90017-7. [DOI] [PubMed] [Google Scholar]
  17. Luyten G. P., Hoogeveen A. T., Galjaard H. A fluorescence staining method for the demonstration and measurement of lysosomal enzyme activities in single cells. J Histochem Cytochem. 1985 Sep;33(9):965–968. doi: 10.1177/33.9.3926869. [DOI] [PubMed] [Google Scholar]
  18. MacGregor G. R., Caskey C. T. Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. Nucleic Acids Res. 1989 Mar 25;17(6):2365–2365. doi: 10.1093/nar/17.6.2365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Murphy C. S., Meisner L. F., Wu S. Q., Jordan V. C. Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1777–1788. doi: 10.1016/0277-5379(89)90348-9. [DOI] [PubMed] [Google Scholar]
  20. Murphy C. S., Pink J. J., Jordan V. C. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res. 1990 Nov 15;50(22):7285–7292. [PubMed] [Google Scholar]
  21. Paik S., Hartmann D. P., Dickson R. B., Lippman M. E. Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Res Treat. 1994;31(2-3):301–307. doi: 10.1007/BF00666162. [DOI] [PubMed] [Google Scholar]
  22. Pink J. J., Bilimoria M. M., Assikis J., Jordan V. C. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer. 1996 Oct;74(8):1227–1236. doi: 10.1038/bjc.1996.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pink J. J., Jiang S. Y., Fritsch M., Jordan V. C. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res. 1995 Jun 15;55(12):2583–2590. [PubMed] [Google Scholar]
  24. Pink J. J., Jordan V. C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res. 1996 May 15;56(10):2321–2330. [PubMed] [Google Scholar]
  25. Pink J. J., Wu S. Q., Wolf D. M., Bilimoria M. M., Jordan V. C. A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 1996 Mar 1;24(5):962–969. doi: 10.1093/nar/24.5.962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ponglikitmongkol M., Green S., Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J. 1988 Nov;7(11):3385–3388. doi: 10.1002/j.1460-2075.1988.tb03211.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sluyser M. Mutations in the estrogen receptor gene. Hum Mutat. 1995;6(2):97–103. doi: 10.1002/humu.1380060202. [DOI] [PubMed] [Google Scholar]
  28. Soule H. D., Vazguez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409–1416. doi: 10.1093/jnci/51.5.1409. [DOI] [PubMed] [Google Scholar]
  29. Tora L., Mullick A., Metzger D., Ponglikitmongkol M., Park I., Chambon P. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 1989 Jul;8(7):1981–1986. doi: 10.1002/j.1460-2075.1989.tb03604.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wei L. L., Mangel W. F., Katzenellenbogen B. S. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro. J Steroid Biochem. 1985 Dec;23(6A):875–881. doi: 10.1016/0022-4731(85)90042-1. [DOI] [PubMed] [Google Scholar]
  31. Welshons W. V., Jordan V. C. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1935–1939. doi: 10.1016/0277-5379(87)90062-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES